Exhibitors Search
MediciBIO
Booth no.
H60
| Exhibition | PARTNERING |
|---|---|
| Country | Korea, South |
| Address | 184 Jungbu-daero, Giheung-gu, Yongin-si, Gyeonggi-do, Republic of Korea |
| Tel (Rep.) | 031-895-6707 |
| Website | http://www.medicibio.com |
Company Introduction
MediciBIO Co., Ltd. is a biotechnology company dedicated to developing advanced gene delivery platforms and innovative genetic therapeutics. Since its foundation in 2021, and inspired by the concept of the “Medici Effect”, MediciBIO has generated breakthrough ideas by integrating drug delivery systems (DDS) with biotechnology, creating a novel fusion technology that positions us for the future era of gene therapeutics.
We focus on the research and development of next-generation lipid nanoparticle (LNP) technologies as clinically validated gene delivery tools, along with RNA-based therapies that include treatments for ocular genetic diseases, vaccines and cancer therapeutics.
We focus on the research and development of next-generation lipid nanoparticle (LNP) technologies as clinically validated gene delivery tools, along with RNA-based therapies that include treatments for ocular genetic diseases, vaccines and cancer therapeutics.
Promotional video
Exhibit Item
MediciBio’s next-generation LNP platform consists of systemic, local, and organ-targeted delivery systems. Systemic LNPs provide excellent gene delivery with repeat dosing, local LNPs reduce unnecessary systemic exposure to enhance safety, and organ-targeted LNPs use proprietary lipids for precise delivery to organs such as spleen and lungs. This differentiated technology is broadly applicable to next-generation genetic therapeutics, including mRNA treatments and vaccines. In RNA therapeutics, we are developing a mutation-selective ASO for Avellino corneal dystrophy, a rare disorder. This therapy selectively suppresses mutant TGFBI mRNA, demonstrating safety and efficacy, and its eye-drop formulation offers convenient administration with potential to become world’s first approved treatment
Exhibit Item Images
-
Product Name : Next Generation Lipid Nanoparticle(LNP) PlatformBased on a next-generation LNP platform, our gene delivery solutions include systemic LNPs offering strong gene delivery with repeat dosing, local LNPs minimizing unnecessary systemic exposure to enhance safety, and organ-targeted LNPs using proprietary lipids for selective delivery to organs such as spleen and lungs.
-
Product Name : ASO Therapeutic for Avellino Corenal DystrophyAvellino corneal dystrophy (ACD) is a severe ocular genetic disorder caused by the TGFBI R124H mutation, with no approved treatment available. We are developing the world’s first oligonucleotide eye drop that selectively suppresses mutant mRNA, demonstrating efficacy and safety in animal models.
Exhibit Description
MediciBio is advancing a next-generation LNP platform that enables safe and efficient gene delivery, serving as a core technology for mRNA therapeutics and vaccines. We are also pioneering the world’s first ASO eye-drop therapy for Avellino corneal dystrophy, leading the way in innovative treatment.
Co-Exhibitor or
Partner’s Information
| Company Name | Country |
|---|---|
KYUNGYON EXHIBITION CORP.